Compare Adaptive Biotechnologies Corp (ADPT) vs Agora Inc (API) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Agora, Inc. (API) trades at $4.11, up 2.49% today, showing improved fundamentals with a shift to profitability in 2025 after years of losses. The stock carries a bullish 60% analyst buy rating despite bearish technical signals. Recent earnings beats and strong cash flow generation highlight operational turnaround, though valuation metrics present a mixed picture with low P/B ratio but elevated P/E.

The outlook suggests potential upside from continued AI-driven growth and possible strategic moves, but risks include competitive pressures and the sustainability of recent margin improvements. Investors should weigh the attractive valuation against execution risks in the evolving conversational AI market.